Showing posts with label Cancer Biology. Show all posts
Showing posts with label Cancer Biology. Show all posts

Thursday, October 3, 2013

Gaurdian Angels

TP53 is the  most studied and important genes present in our genome which codes for p53. p53 is one of the three sisters, as they say, along with p63 and p73. All these proteins are the transcription factors which regulate the expression of the required protein appropriate for situation in the cell. But unlike other siblings, p53 has shorter half life because of absence of the stabilizing domain. P53 is tumor suppressor or stress responder, they are ultimate protector of integrity of our somatic genome. Thus it’s a major fidelity factor in the cell. p53 acts as a tumor suppressor, which means that it regulates cell division by keeping cells from growing and dividing too fast or in an uncontrolled way. But it’s not that simple as it sounds, it’s a key player in so many cellular pathways that defining its role gets difficult.
Tumor protein p53 is located in the nucleus of cells throughout the body, where it binds directly to DNA. When the DNA in a cell becomes damaged by agents such as toxic chemicals, radiation, or ultraviolet (UV) rays from sunlight, this protein plays a critical role in determining whether the DNA will be repaired or the damaged cell will self-destruct (undergo apoptosis). If the DNA can be repaired,  p53 activates other genes to fix the damage. If the DNA cannot be repaired, this protein prevents the cell from dividing and signals it to undergo apoptosis. This process prevents cells with mutated or damaged DNA from dividing, which helps prevent the development of tumors. Because  p53 is essential for regulating cell division and preventing tumor formation, it has been rightly nicknamed as the "guardian of the genome."
This family of gene has been conserved for billions of years seen from invertebrates to vertebrates. This conservation is obliviously due to its function and protection against all kind of stress. Thus it becomes an evolutionary advantageous as stress is the thing which all beings should be able to handle without compromising the fidelity of their genome. Thus this family has been incharge of fidelity through billion years of evolutionary history. In this process, p63/73 became germline fedility factor while p53 became a somatic fedility factor.
Huge amount of research is been done in this field giving insight into overall working of this family.  I think this research will open to us to vast realms of therapeutics for range of diseases.
Got this fun video on p53! Click!

Wednesday, April 25, 2012

Study of growth property of complement C2 produced by THP-1 cells using the chemical agents –Histamine, Imidazole and β- Glycyrrhetinic acid

ABSTRACT:

Despite significant research on the role of inflammation and immunosurveillance in the immunologic microenvironment of cancer, little attention has been given to the oncogenic capabilities of the complement cascade. The complement system is the major branch of the humoral immune system.  Complement components C2 and factor B are essential for the classical and alternative pathways of complement activation, respectively, because they provide catalytic subunits for the C3 and C5 convertases, both of which are key enzymes for the complement system. Monocytes and macrophages synthesize complement proteins, thus providing an essential local source of these proteins in vivo which serve as a first-line host defense mechanism. The recent findings have shown that complement factor especially Factor B and C2 facilitates cellular proliferation and regeneration. We address this hypothesis using chemical agents Histamine, Imidazole and β- Glycyrrhetinic acid who individually influence the factor C2 production in THP-1 cells (human monocytic leukemia cell line). We investigated the growth property of complement C2 by studying the effect of these three chemical agents on the growth of THP-1 cells in time and concentration dependent manner. In this study, to our knowledge we have shown that the Complement C2 has a proliferating effect on monocytic leukemia cells. Additionally, the results show that these three chemical agents do have an influence on each other’s growth properties. Given that the traditionally held functions for the complement system include innate immunity and cancer defense, our study suggests a new way of thinking about the role of complement proteins in monocytes especially human monocytic leukemia. These results may give us leads for the treatment of monocytic leukaemias like AML-M5 which are difficult to treat.

Key words: Cancer, Complement C2, Factor B, Histamine, Imidazole and β- Glycyrrhetinic acid, THP-1, AML-M5.

For the whole article click on the link below:

https://docs.google.com/open?id=0BzdHWb7McaBDRG0tNmNFTGg2Tzg 

Tuesday, April 3, 2012

Differentiation Therapy and AML

Abstract:

Acute myelocytic leukaemia (AML) is a clonal disorder that is the consequence of acquired somatic mutations in hematopoietic progenitor cells that block normal differentiation and cell death and confer a proliferative growth advantage (Wang R. et. al., 2006). AML is basically a group of malignant bone marrow neoplasms of myeloid precursors of white blood cells.

The symptoms can be aspecific: asthenia, pallor, fever, dizziness and respiratory symptoms. Diagnostic methods include blood analysis, bone marrow aspirate for cytochemical, immunological and cytogenetical analysis, and cerebrospinal fliud (CSF) investigations. Treatment includes intensive multidrug chemotherapy and in selected cases allogenic bone marrow transplantation. Nevertheless, outcome of AML remains poor with overall survival of 35-60%. New therapeutics are required to increase the probability of cure in this serious disorder (Verschuur A. C. et. al., 2004).

Differentiation therapy has been successful as a novel treatment for APL. Several compounds including dimethyl sulfoxide, retinoic acid, phorbol ester and 1, 25-dihydroxy vitamin D3 induce AML cells to differentiate toward mature cells. Among them, retinoic acid induces AML cells to differentiate toward granulocytes, whereas 1, 25-dihydroxy vitamin D3 induces AML cells to differentiate toward monocytes (Hyun-Ock Pae a,b et. al., 2001). The following is the overview of advancement in Differentiation therapy against AML specifically AML-M5.

Key words:
AML, Hematopoietic, Symptoms, Daignostic, Therapeutics, Differentiation Therapy.

For full review click on the link below:
https://docs.google.com/open?id=0BzdHWb7McaBDM3VZMEdMS3pSdm1TSEJJbzc5UVNCUQ

Sunday, March 18, 2012

Study of growth property of complement C2 produced by THP-1 cells using the chemical agents –Histamine, Imidazole and β- Glycyrrhetinic acid

Complement System:

The complement system is the major branch of the humoral immune system. It offers a powerful defense against infection and is tightly regulated to prevent damage to self by functionally equivalent soluble and membrane regulators (Kindt T. J., 2007).

The complement system consists of a series of plasma proteins that plays an important role in host defence. There are three pathways to complement activation. The classical pathway initiates with the formation of an antibody C1q complex on the surface of a pathogen or pathogen infected cell. This complex, in turn, activates C2 via serine proteases and is itself also a serine protease. The protein C2a combines with newly cleaved protein C4a to generate a C3 convertase, C2aC4b. C3b forms the central protein complex of the complement system either by binding to complement receptors or by complexing with C2aC4b to form C5 convertase, C2aC4bC3b. This complex can bind and stabilize C5a that forms the central effector function of the complement system around which proteins C5-C9 will bind and cooperatively lyse the cell (Kindt T. J., 2007). The mannose binding pathway has a similar cascade as the classical pathway but functions independently of antibody formation. Instead, MASP1 (Mannan-binding lectin serine protease 1) and MASP2 (Mannan-binding lectin serine protease 2) binds to the mannose structures commonly found on pathogens. The Mannan-binding lectin complex is closely homologous to C1q and can activate C2 and C4. In the absence of sialic acid sugars present on normal somatic cells and which are rare on pathogens, C1q begins a lytic cascade. There is a third pathway for complement activation that begins with spontaneous activation of complement proteins. In this pathway the thioester bonds in C3 undergo hydrolysis which allows the binding of Factor B and its subsequent cleavage by plasma protease Factor D. C3b from C3 and Factor Bb from Factor B combine to form a C5 convertase (Nielsen D. G., 2009).

C3a, C4a and C5a produced acts as anaphylatoxin and regulate vasodilatation, increase permeability of blood vessels, and trigger degranulation and oxidative burst from neutrophils, eosinophiles, and basophiles. They mainly act on specific receptors to produce local inflammatory responses and when secreted in concentrations high enough to invoke a general systemic response, they cause circulatory collapse similar to an IgE mediated allergic response. They modulate the secretion of IL-6, and TNFα from B cells and serve as potent chemoattractants. C5a also works directly on neutrophils and monocytes to increase adhesion molecules, migration, and phagocytosis (Nielsen D. G., 2009).

For the whole artical click on the link below:

https://docs.google.com/open?id=0BzdHWb7McaBDSldlNUkzajBTa200Zkl0bzdKbWo2UQ


Saturday, January 28, 2012

Genomic techniques used to find new diagnostic markers for testicular cancer

Numerous recent studies have demonstrated the use of genomic data, particularly gene expression signatures, as clinical prognostic and diagnostic factors in cancer. This review highlights the usage of genomic analysis to detect diagnostic markers for testicular cancer. The carcinoma in situ (CIS) cell is the common precursor of nearly all testicular germ cell tumours (TGCT). So, there is a particular need of novel markers specific to CIS and various molecular techniques are been used for the same. In particular, the focus is on recent studies showing successful usage of microarray technology, tools used for its analysis and finally a glimpse of role of Comparative Genomic Hybridisation (CGH) in discovery of new markers for CIS diagnosis.